Incannex healthcare completes phase 2 enrollment in reposa phase 2/3 trial of ihl-42x, an oral once-daily treatment for obstructive sleep apnea (osa)

New york and melbourne, australia, april 03, 2025 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the company has completed phase 2 patient enrollment in the global phase 2/3 reposa study of ihl-42x for the treatment of obstructive sleep apnea (osa). ihl-42x is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.
IXHL Ratings Summary
IXHL Quant Ranking